Acrivon therapeutics reports positive endometrial cancer data from ongoing acr-368 registrational intent phase 2 study at esmo, advancement of acr-2316 into clinic ahead of timelines, and progress on its ap3 interactome for proprietary data analysis

Watertown, mass., sept. 14, 2024 (globe newswire) -- acrivon therapeutics, inc. (“acrivon” or “acrivon therapeutics”) (nasdaq: acrv), a clinical stage precision medicine company utilizing its acrivon predictive precision proteomics (ap3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, today presented additional positive clinical data at esmo from the ongoing registrational intent, multicenter phase 2 trial of acr-368 in patients with locally advanced or metastatic, recurrent endometrial cancer. the company has also disclosed that the investigational new drug (ind) application for its next clinical candidate, acr-2316, has been cleared by the fda with initial clinical sites now activated, and first-in-human dosing for the phase 1 study expected in the fourth quarter of 2024.
ACRV Ratings Summary
ACRV Quant Ranking